Hot Investor Mandate: Taiwan VC Invests in Biomaterials, Medical Device, and Digital Health Companies, Open to Cross-Border Investment Opportunities

3 Aug

A venture capital firm in Taipei, Taiwan invests in several sectors including biotechnology, semiconductors, commerce, materials, and software. The firm will invest in companies in Series A and B in Taiwan, Japan, and the U.S. Typical check size ranges from $1-3M USD for early-stage deals. The firm also has an angel fund for Seed stage companies with typical check sizes ranging from $100-3000k USD. Currently, 70% of the firm’s portfolio companies are in Taiwan or Taiwanese-related and 30% are in the U.S. or Japan. The firm has an extended network in the U.S., especially from the Silicon Valley and Boston as most of the founding partners are from Stanford University. If the firm is investing in a Taiwanese company, they tend to lead investments, but for overseas investments, the firm will mostly act as a co-investor.

The firm focuses on biomaterials, medical devices and digital health at in-development or clinical stages. The firm does not invest in pharma or drug development. In terms of medical devices, the firm likes to look at surgery-related devices and for digital health, the firm like to look at software for long-term care. Though, firm is open to all indications and can look at orphan diseases depending on the technology.

The firm focuses on companies that can finalize assets by maximum of 9 years due to the limited fund. The firm may take an observer seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment